A few days ago, Jufeel International Group formally submitted materials to the Tanzania Food and Drug Administration (TFDA) for its PMAS biologicals, applying for conversion from auxiliary drugs to standard drugs. After obtaining the standard drug number, the PMAS biologicals will be sold in 17 African Union(AU) countries, instead of only 6 East African Community(EAC) countries, namely Tanzania, Kenya, Rwanda, Burundi, Uganda and south Sudan.Professor Malebo of the IGOGO team, special adviser to the President of Tanzania and TFDA staff held a special seminar on the pharmacology of PMAS biologicals and its market development in East Africa.

　　PMAS biologicals is a biological mainly composed of acemannan extracted from natural Curacao aloe vera, which can quickly improve human immunity and thus become an adjuvant therapeutic drug to inhibit the replication of HIV. Based on the fact that acemannan can produce rapid and efficient antiviral and anti-tumor activity in vivo, it can also be used as a cancer inhibitor to replace chemotherapy drugs. It is an reverse growth factor first proposed and proved by the scientific research team of JUFEEL Natural Medicine R&D Center, School of Pharmacy and Life Sciences, Changzhou University, led by professor Zhang rongxuan, chief scientist of Jufeel Group, and it is also a kind of aloe vera biologicals achievement that can quickly restore the immunodeficiency system. At present, Jufeel cooperated with Zhejiang University to study the development of new natural polysaccharide compound PMAS as new drugs against HIV. University and enterprises cooperated to provide new drugs and new therapeutic strategies to solve the world's public health problems.

　　In 2017, Jufeel donated worth $5.3 million aloe polysaccharide extract PMAS to the National Institute of Medical Research (NIMR) of Tanzania. With the approval of Tanzania, NIMR and ten affiliated hospitals have carried out the phase i clinical trial of PMAS in treating AIDS. After a three-month clinical study of 38 AIDS patients, the average HIV viral load in the blood of the patients decreased by 73.6%, and 7 of them tested without carrying HIV virus.

　　In January 2019, Jufeel and Tanzania PMAS Co., Ltd. signed an agreement on the phase ii clinical trial of "PMAS biologicals" for the treatment of AIDS. At the end of April, another 1,950 boxes of PMAS biologicals donated by Jufeel, worth $5 million, arrived at the Tanzanian port of Dar es saddam. Results of this batch of PMAS biologicals in the treatment of HIV clinical trial has received high attention from many AIDS patients in the city of Dar es saddam, Tanzania. According to the Tanzanian related staff, they also attracted a late-stage HIV disease patient for its fame. The patient was informed that the PMAS biologicals from China has a very significant effect on the treatment of AIDS. He specially came to the office of Mr. IGOGO, director of the Tanzania PMAS Co., Ltd. and asked for help to save his life. Mr. IGOGO brought the patient to the local hospital and treated him with PMAS adhering to the concept of the head office with both a benevolent mind and heart to save the world .

　　According to information, after "PMAS biologicals" entering into EAC countries like Tanzania, it will also quickly contact the Southern African Development Community (SADC), and cooperate with aid organizations such as the Red Cross Societies, AIDS Society, Aid Organizations for Central Africa, World Health Organization to let China’s advanced biotechnology to save more AIDS patients.